Pramiconazole
 |
{{Drugbox | Verifiedfields = changed | verifiedrevid = 366890982 | IUPAC_name = 1-{4-[4-(4-{[(2R,4S)-2-(2,4-difluorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazin-1-yl]phenyl}-3-isopropylimidazolidin-2-one | image = Pramiconazole.png | width = | image2 = | width2 = | imagename = | drug_name =
| tradename = | pregnancy_AU = | pregnancy_US = | pregnancy_category = | legal_AU = | legal_CA = | legal_UK = | legal_US = | legal_status = | routes_of_administration =
| bioavailability = | protein_bound = | metabolism = | elimination_half-life = | excretion =
| CAS_number_Ref = 
| CAS_number =
| ATC_prefix = none
| ATC_suffix =
| ATC_supplemental =
| PubChem = 11411233
| DrugBank_Ref =
| DrugBank =
| UNII_Ref = 
| UNII = 4SYH0R661F
| ChEMBL_Ref =
| ChEMBL = 175797
| PubChem = 3013050
| ChemSpiderID = 2281806
| chemical_formula = | C=35 | H=39 | F=2 | N=7 | O=4 | molecular_weight = 659.725 g/mol | smiles = CC(C)N1CCN(C1=O)c2ccc(cc2)N3CCN(CC3)c4ccc(cc4)OC[C@H]5OC[C@](O5)(Cn6cncn6)c7ccc(cc7F)F | InChI = 1/C35H39F2N7O4/c1-25(2)43-17-18-44(34(43)45)29-6-4-27(5-7-29)40-13-15-41(16-14-40)28-8-10-30(11-9-28)46-20-33-47-22-35(48-33,21-42-24-38-23-39-42)31-12-3-26(36)19-32(31)37/h3-12,19,23-25,33H,13-18,20-22H2,1-2H3/t33-,35+/m0/s1 | InChIKey = AEKNYBWUEYNWMJ-QWOOXDRHBI | StdInChI = 1S/C35H39F2N7O4/c1-25(2)43-17-18-44(34(43)45)29-6-4-27(5-7-29)40-13-15-41(16-14-40)28-8-10-30(11-9-28)46-20-33-47-22-35(48-33,21-42-24-38-23-39-42)31-12-3-26(36)19-32(31)37/h3-12,19,23-25,33H,13-18,20-22H2,1-2H3/t33-,35+/m0/s1 | StdInChIKey = AEKNYBWUEYNWMJ-QWOOXDRHSA-N }}
Pramiconazole is a triazole antifungal undergoing research for the treatment of acute skin and mucosal fungal infections.
It is developed by Barrier Therapeutics.
 | This antiinfective drug article is a stub. You can help Wikipedia by expanding it. |